Every routine blood panel includes fasting glucose. Most don’t include fasting insulin. That gap matters more than most people realize, because fasting insulin moves first — often a decade or more before blood glucose begins to climb — and by the time glucose enters the prediabetic range, meaningful beta-cell stress and cardiovascular risk have typically been building for years.
Understanding both tests, what each measures, what each misses, and why the combination tells a story neither can tell alone gives you a much sharper picture of your actual metabolic health than glucose alone ever could.
What fasting glucose measures — and what it doesn’t
Fasting glucose measures the concentration of sugar in your blood after at least eight hours without food. Your body maintains blood sugar within a narrow range through a tightly regulated feedback system involving the pancreas, liver, and cells throughout your body. Fasting glucose is a snapshot of how well that system is currently performing.
The normal reference range for fasting glucose sits below 100 mg/dL. A reading between 100 and 125 mg/dL indicates prediabetes. Above 126 mg/dL on two separate tests confirms type 2 diabetes. These are the thresholds the American Diabetes Association (ADA) uses, the thresholds your doctor uses, and the thresholds that determine whether anyone acts.
Here is the problem: fasting glucose is a lagging indicator. It reflects the output of a system working to maintain balance, not whether that balance is effortful or easy. A blood sugar reading of 92 mg/dL tells you your glucose is normal. It tells you nothing about how much insulin your pancreas had to produce to keep it there. The answer to that question matters enormously — and fasting insulin is how you answer it.
What fasting insulin measures — and why it moves first
Fasting insulin measures the amount of insulin circulating in your blood after an overnight fast. Insulin is the hormone your pancreas releases in response to rising blood glucose. Its job is to signal your muscle, fat, and liver cells to absorb glucose from the bloodstream. When those cells respond well — when they are insulin-sensitive — the pancreas releases a modest amount and glucose drops quickly. Cells that start ignoring insulin’s signal — a condition called insulin resistance — force the pancreas to compensate by producing more. And more. And then more still.
That compensatory insulin production is the key mechanism. As cells become progressively resistant, fasting insulin climbs while fasting glucose stays normal, because the system is still working — it’s just working much harder. Gerald Reaven described this dynamic in his landmark 1988 Banting Lecture, proposing that insulin resistance and the resulting hyperinsulinemia sit at the center of a cluster of metabolic abnormalities including glucose intolerance, hypertension, and dyslipidemia.
Longitudinal data confirm that insulin sensitivity begins declining and insulin secretion begins rising years before fasting glucose crosses any diagnostic threshold (Tabak et al., 2009). The pancreas can maintain normal glucose for years — even a decade or more — by simply producing more insulin. This silent phase of elevated insulin with normal glucose represents a window where metabolic dysfunction accumulates while standard blood work looks perfectly reassuring.
The reference ranges — and the optimal ranges
Fasting glucose:
| Result | Interpretation |
|---|---|
| Below 70 mg/dL | Hypoglycemia — too low |
| 70–99 mg/dL | Normal |
| 100–125 mg/dL | Prediabetes / impaired fasting glucose |
| 126 mg/dL or above | Diabetes (confirmed on repeat testing) |
Fasting insulin:
Standard laboratory reference ranges for fasting insulin typically run up to 20–25 µIU/mL — a range that encompasses much of the population, including many people with meaningful insulin resistance. Longevity-focused clinicians draw a sharper line, based on epidemiological cohort data:
| Result | Interpretation |
|---|---|
| 2–6 µIU/mL | Optimal — associated with lowest metabolic risk |
| 6–10 µIU/mL | Acceptable — begin monitoring more closely |
| 10–15 µIU/mL | Elevated — suggests early insulin resistance |
| Above 15 µIU/mL | High — consistent with established insulin resistance |
A large prospective cohort published in JAMA Internal Medicine (n=14,033, follow-up 9.4 years) found a graded, continuous relationship between fasting insulin and all-cause mortality even within the conventionally “normal” range. Participants with fasting insulin below 7 µIU/mL showed the lowest hazard for cardiovascular events after full adjustment for age, BMI, lipids, and smoking. The San Antonio Heart Study, tracking 2,569 adults over 7.5 years, found that fasting insulin above 12.7 µIU/mL predicted incident type 2 diabetes with an odds ratio of 3.1 (95% CI 2.2–4.4) after adjustment for glucose tolerance status. Participants with fasting insulin below 6 µIU/mL showed no significant excess risk.
The practical implication: being told your fasting insulin is “normal” by conventional lab reference ranges is not the same as having optimal insulin sensitivity. A reading of 18 µIU/mL sits within many labs’ reference ranges, yet it signals a metabolic trajectory that is fully reversible with early intervention.
HOMA-IR: combining both to get a sharper picture
The most informative single number combining both tests is the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). Developed at Oxford in 1985, it remains one of the most widely validated clinical tools for insulin resistance quantification.
The formula:
HOMA-IR = (Fasting insulin in µIU/mL × Fasting glucose in mg/dL) ÷ 405
If glucose is measured in mmol/L, divide by 22.5 instead. Both values must come from fasting blood samples taken after an 8–12 hour overnight fast.
HOMA-IR interpretation:
| Score | Interpretation |
|---|---|
| Below 1.0 | Optimal insulin sensitivity |
| 1.0–1.9 | Normal range for most adult populations |
| 1.9–2.9 | Early insulin resistance — warrants attention |
| Above 2.9 | Significant insulin resistance |
A meta-analysis of seven prospective observational studies covering 26,976 non-diabetic adults found that the highest category of HOMA-IR carried a 34% higher risk of all-cause mortality and a 111% higher risk of cardiovascular mortality compared to the lowest category. Fasting insulin alone showed a smaller and less statistically robust association, suggesting that the combined picture HOMA-IR provides is genuinely more informative than either measurement alone.
Tracking HOMA-IR over time turns insulin resistance from an abstract concept into a concrete, measurable target. A drop from 2.8 to 1.3 after dietary and exercise changes represents a real, quantified reduction in cardiovascular and diabetes risk — not a vague sense of improvement.
Why this matters beyond diabetes
Insulin resistance is not just a precursor to type 2 diabetes. Elevated insulin drives metabolic dysfunction across multiple organ systems, and its consequences accumulate during the years when fasting glucose still reads normal.
Cardiovascular disease. Chronically elevated insulin promotes endothelial inflammation, accelerates arterial plaque formation, and independently predicts cardiovascular events. Elevated HOMA-IR associates with hypertension, dyslipidemia, and endothelial dysfunction beyond its association with glucose abnormalities.
Polycystic ovary syndrome (PCOS). Insulin resistance drives androgen excess in PCOS. HOMA-IR is a central component of PCOS evaluation and treatment monitoring, and improving insulin sensitivity often improves hormonal and menstrual parameters directly.
Non-alcoholic fatty liver disease (NAFLD). HOMA-IR correlates directly with hepatic fat accumulation and NAFLD severity. Elevated insulin promotes fat storage in the liver; improving insulin sensitivity is the primary mechanism by which dietary interventions reverse NAFLD.
Fat storage and weight resistance. Chronically elevated insulin actively promotes fat storage — particularly visceral abdominal fat — while suppressing the body’s ability to mobilize stored fat for energy. People with insulin resistance often struggle to lose weight despite caloric restriction because the hormonal environment fundamentally favors fat storage. Normalizing insulin sensitivity is frequently the intervention that makes weight loss accessible for the first time.
Certain cancers. Insulin acts as a growth factor at high concentrations. Epidemiological data link hyperinsulinemia to increased risk of colorectal, endometrial, and breast cancers, among others.
Cognitive function. Research on brain glucose metabolism and insulin resistance — covered in detail in Keep Health’s Outthink Your Brain article — finds that insulin resistance impairs brain glucose uptake and associates with elevated dementia risk.
When each test tells a different story
The scenario that makes fasting insulin most clinically valuable: a person with normal fasting glucose and an elevated fasting insulin. This combination — sometimes called “euglycemic hyperinsulinemia” — describes someone whose glucose looks fine but whose system is working hard to keep it there. By conventional medicine’s standards, their metabolic health is normal. By any meaningful assessment of trajectory, they are on a path toward metabolic dysfunction that early intervention can reverse.
The opposite scenario also matters. Fasting glucose can be elevated while fasting insulin remains low — a pattern that may indicate beta-cell fatigue, where the pancreas has lost its capacity to compensate. At that stage, the window for reversing insulin resistance with lifestyle alone has narrowed. Earlier identification — via elevated fasting insulin before glucose rises — is exactly what makes fasting insulin the more actionable early marker.
Who should get tested and how often
Given that fasting insulin detects metabolic dysfunction years earlier than fasting glucose, the more useful question is who should not get tested — and the honest answer is that most adults would benefit from having both markers tracked together.
That said, fasting insulin testing makes particular sense if any of the following apply:
- Family history of type 2 diabetes, metabolic syndrome, or cardiovascular disease
- Central or abdominal weight gain, particularly with difficulty losing it
- Fatigue, persistent hunger, or energy crashes after meals
- Polycystic ovary syndrome or irregular menstrual cycles
- Fatty liver diagnosis (NAFLD) or elevated liver enzymes
- Blood pressure creeping up without a clear cause
- Skin changes including darkening patches in skin folds (acanthosis nigricans)
Frequency: if results are optimal, checking annually at your health baseline assessment makes sense. If insulin or HOMA-IR are elevated and you’re making lifestyle changes, retesting every three to six months provides useful feedback on trajectory.
Practical requirements for accurate results: fast for 8–12 hours before the draw; water is fine. Avoid vigorous exercise the morning of the test — exercise temporarily alters both glucose and insulin. Ask specifically for fasting insulin and fasting glucose together; many standard panels omit the insulin component entirely.
How to improve fasting insulin and HOMA-IR
The interventions with the strongest evidence for improving insulin sensitivity are also the interventions Keep Health covers as foundational for longevity. This alignment is not coincidental — insulin resistance sits near the center of the metabolic dysfunction that underlies most chronic disease.
Exercise — the most powerful single intervention. Both aerobic exercise and strength training improve insulin sensitivity through distinct mechanisms. Aerobic exercise increases glucose uptake in muscle through insulin-independent pathways. Resistance training increases muscle mass — and skeletal muscle is the body’s largest glucose disposal site. A modest 5–10% weight reduction from exercise produces meaningful improvements in HOMA-IR. VO2 max improvement tracks closely with insulin sensitivity gains in endurance training.
Dietary changes. Reducing refined carbohydrates and added sugars lowers the glycemic and insulinemic load on the pancreas. Intermittent fasting and caloric restriction reduce fasting insulin through reduced insulin secretion during the fasting window. The Mediterranean and whole-food dietary patterns Keep Health covers in Don’t Die from Diet consistently improve HOMA-IR in intervention studies. Importantly, dietary macronutrient composition interacts with baseline insulin status — people with higher baseline insulin resistance respond differently to high-carbohydrate vs. high-fat dietary patterns, which is one reason individualized approaches outperform generic dietary advice.
Sleep. Even a few nights of poor sleep acutely impairs insulin sensitivity. Chronic sleep deprivation associates with significantly elevated HOMA-IR. Keep Health’s Sleep Well article covers the mechanisms in detail.
Stress management. Cortisol directly impairs insulin signaling. Chronic psychological stress drives chronic cortisol elevation, which in turn drives chronic insulin resistance. Stress Less covers practical interventions.
Medications. Metformin improves insulin sensitivity primarily through hepatic mechanisms. GLP-1 receptor agonists — covered in Keep Health’s peptides article — show strong insulin-sensitizing effects alongside weight loss. Neither replaces lifestyle intervention; both work best as complements to it. Discuss with your personal health team.
The honest bottom line
Fasting glucose is useful. It catches frank diabetes reliably and it guides treatment decisions in people with established glycemic abnormalities. For detecting the metabolic dysfunction that precedes diabetes — often by a decade or more — it is a poor early-warning tool.
Fasting insulin is better. Moving earlier in the disease trajectory, it captures the compensatory burden that normal glucose hides and predicts cardiovascular and metabolic outcomes with greater sensitivity in people who are metabolically at risk but not yet diabetic. The combination of fasting insulin and fasting glucose in the HOMA-IR calculation outperforms either test alone as a predictor of all-cause and cardiovascular mortality in non-diabetic adults.
If your routine blood work includes fasting glucose but not fasting insulin, ask for both at your next visit. The test costs very little. The information it provides — about where you are on the metabolic trajectory and whether your interventions are working — is disproportionately valuable.
Frequently asked questions
Why doesn’t my doctor order fasting insulin routinely?
Fasting insulin is not part of standard metabolic panels because clinical guidelines for diabetes diagnosis rely on fasting glucose, HbA1c, and oral glucose tolerance testing — not insulin. Most insurance coverage follows those guidelines. Functional medicine and longevity-focused practitioners are more likely to order it routinely. You can request it explicitly at your next lab draw; most labs offer it as an add-on, and many direct-to-consumer testing services include it in metabolic panels.
What is a normal fasting insulin level?
Standard laboratory reference ranges typically run up to 20–25 µIU/mL. From a longevity and metabolic health perspective, the optimal target is 2–6 µIU/mL. Readings above 10 µIU/mL suggest early insulin resistance even when fasting glucose remains normal. Context matters — discuss your specific result with a physician rather than interpreting it in isolation.
What is HOMA-IR and how do I calculate it?
HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. The formula is: (fasting insulin in µIU/mL × fasting glucose in mg/dL) ÷ 405. A HOMA-IR below 1.0 indicates optimal insulin sensitivity. Scores between 1.9 and 2.9 suggest early insulin resistance; above 2.9 indicates significant insulin resistance. Many labs now calculate and report it automatically alongside the individual values.
Can I have insulin resistance with normal blood sugar?
Yes — this is the central insight of fasting insulin testing. The pancreas can maintain normal fasting glucose for years, even decades, by producing progressively more insulin. During that period, fasting insulin is elevated, HOMA-IR is elevated, and metabolic damage is accumulating — but standard blood work looks normal. Fasting insulin testing identifies this silent phase, which is why it is more useful than fasting glucose alone as an early-warning tool.
